On Thursday, Intellia Therapeutics Inc NTLA outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. NTLA-2002 is advancing in the pivotal Phase 3 HAELO study for HAE, following promising Phase 2 results demonstrating the potential to eliminate chronic treatments after a one-time infusion. Meanwhile, nex-z has shown robust results in the Phase 3 MAGNITUDE study for ATTR amyloidosis, with clinical evidence suggesting the therapy could halt or re ...